Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous stem cell therapy, as investigated by the University of Campania Luigi Vanvitelli, involves the intra-cardiac infusion of a patient's own stem cells to treat advanced heart failure. This therapeutic approach is specifically designed for patients with chronic heart failure who are refractory to standard medical treatments and have previously received an internal cardioverter-defibrillator (ICD). By delivering stem cells directly into the heart tissue, the treatment aims to stimulate myocardial repair, enhance left ventricular functionality, and reduce the frequency of hospitalizations. Clinical evaluation focuses on improvements in NYHA functional class and the reduction of symptoms such as angina in patients with a history of myocardial infarction and coronary artery revascularization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous stem cell therapy.